Login to Your Account



Yes and No: FDA Panel Votes Shyly in Favor of Mipomersen

By Randy Osborne
Staff Writer

Friday, October 19, 2012

Kynamro (mipomersen) for homozygous familial hypercholesterolemia (HoFH) overcame testimony about liver problems, cancer in mice, possible cardiac risk, troubling immune responses and significant trial dropout rates to win a vote recommending approval from an FDA advisory panel.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription